Overview

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2025-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Junshi Bioscience Co., Ltd.